… be attributable to the poor PS of the patient population in our study. In a phase II study of 72
… This proof of principle randomized phase II study confirms that poor PS patients (PS 2 or 3) …

… We conducted a multicenter randomized phase II trial to evaluate two schedules of single-agent
docetaxel in the first-line treatment of elderly and performance status (PS) 2 patients with …

… , the mind-set toward poor PS patients is also slowly … of poor PS (ECOG 2 and 3) and/or
elderly (70 years or older) patients with advanced NSCLC in the context of a randomized phase II …

… To further investigate the optimal treatment for elderly and poor performance status patients,
we performed a randomized phase 3 study that compared single-agent versus combination …

… in a subsequent randomized trial in which patients in good performance status were treated
… from another randomized phase II trial designed to suit patients in poor performance status. …

… We conducted a randomized phase II trial that involved weekly regimen of cisplatin combined
with gemcitabine or docetaxel in elderly or poor performance status (PS) patients with …

7057 Background: Docetaxel has been used in elderly and PS 2 pts with advanced NSCLC
with acceptable toxicity. However, myelosuppression can be severe on the every 3-week …

… randomized phase II study with two experimental treatment arms in which each individual
treatment arm was structured as an independent phase … a relatively small randomized phase II …

… Findings In this randomized phase 3 clinical trial of 96 patients with NSCLC, hypofractionated
IGRT failed to demonstrate an improvement in overall survival compared with CFRT. …

… A multicenter randomized phase II trial to evaluate two treatment strategies in the first-line
management of advanced non–small-cell lung cancer (NSCLC) patients with a performance …